Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
Press OW, Eary JF, Applebaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER 2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increased anticancer activity: A randomized, multinational controlled phase III trial
abstr
Slamon DJ et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER 2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increased anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98a (abstr).
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
Sievers EL, Appelbaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-3684.
Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's c colorectal carcinoma: German Cancer Aid 17-1A Study Group
Riethmuller G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma: German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-1183.
Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
Foon KA et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995;96:334-332.
Induction of multiple anti-c-erbB2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment
Clark JI et al. Induction of multiple anti-c-erbB2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother 1997;44:265-272.
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
Adams GP, Schier R, McCall AM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405-1412.
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
Schier R et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996;263:551-567.
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2 and Fab in tumors
Fujimori K, Covell DE, Fletcher JE et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2 and Fab in tumors. Cancer Res 1989;49:5656-5663.
Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for binding site barrier
Juweid MN, Paik R, Perez-Barele C et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier. Cancer Res 1992;52:5144-5153.
Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis
McCall AM, Adams GP, Amoroso AR et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Molecular Immunology 1999;36:433-445.
